Potent Inhibition of Cicatricial Contraction in Proliferative Vitreoretinal Diseases by Statins

Shuhei Kawahara,1 Yasuaki Hata,1 Takeshi Kita,1 Ryoichi Arita,1 Muneki Miura,1 Shintaro Nakao,2 Yasutaka Mochizuki,1 Hiroshi Enaida,1 Tadahisa Kagimoto,3 Yoshinobu Goto,4 Ali Hafezi-Moghadam,2 and Tatsuro Ishibashi1

OBJECTIVE—Despite tremendous progress in vitreoretinal surgery, certain postsurgical complications limit the success in the treatment of proliferative vitreoretinal diseases (PVDs), such as proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR). One of the most significant complications is the cicatrical contraction of proliferative membranes, resulting in tractional retinal detachment and severe vision loss. Novel pharmaceutical approaches are thus urgently needed for the management of these vision-threatening diseases. In the current study, we investigated the inhibitory effects of statins on the progression of PVDs.

RESEARCH DESIGN AND METHODS—Human vitreous concentrations of transforming growth factor-β2 (TGF-β2) were measured by enzyme-linked immunosorbent assay. TGF-β2– and vitreous-dependent phosphorylation of myosin light chain (MLC), a downstream mediator of Rho-kinase pathway, and collagen gel contraction simulating cicatrical contraction were analyzed using cultured hyalocytes. Inhibitory effects of simvastatin on cicatricial contraction were assessed both in vitro and in vivo.

RESULTS—Human vitreous concentrations of TGF-β2 were significantly higher in the samples from patients with PVD compared with those without PVD. Simvastatin inhibited TGF-β2–dependent MLC phosphorylation and gel contraction in a dose- and time-dependent manner and was capable of inhibiting translocation of Rho protein to the plasma membrane in the presence of TGF-β2. Vitreous samples from patients with PVD enhanced MLC phosphorylation and gel contraction, whereas simvastatin almost completely inhibited these phenomena. Finally, intravitreal injection of simvastatin dose-dependently prevented the progression of diseased states in an in vivo model of PVR.

CONCLUSIONS—Statins might have therapeutic potential in the prevention of PVDs. Diabetes 57:2784–2793, 2008

Proliferative vitreoretinal diseases (PVDs), such as proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR), are common causes of severe vision loss (1). Surgical approaches for the treatment of these diseases have evolved significantly in the recent past, but the occurrence of postoperative complications, such as cicatrical contraction, limit the therapeutic success (2). Therefore, there is an urgent need for alternate pharmacological treatments of PVDs that can complement or potentially replace surgical intervention. In PDR and PVR, excessive wound healing and fibrosis induce the formation of proliferative membranes on the retinal surface. The proliferative membrane then extends into the vitreous and contracts, causing tractional detachment (3). The proliferative membrane consists of various cells, including hyalocytes, retinal pigment epithelial cells, glial cells, and fibroblast-like cells (4–7).

Hyalocytes morphologically resemble macrophages and are considered to originate from peripheral blood monocytes (8). Under physiological conditions, hyalocytes are mainly located in the cortical vitreous and are considered to maintain its transparency (9,10). Under pathological conditions, hyalocytes are thought to be critical in vitreoretinal interface diseases, such as idiopathic epiretinal membrane formation, macular hole, and diabetic macular edema (11). Hyalocytes in diabetic eyes are higher in number and of different shape compared with those in normal eyes (12).

Transforming growth factor-β (TGF-β) is pivotal to tissue fibrosis. Among the three isoforms of TGF-β, TGF-β2 is the predominant isoform in the vitreous (13,14). We and others have shown that TGF-β2 is overexpressed in the epiretinal membrane and vitreous of PDR and PVR patients and that its expression correlates with the presence of intraocular fibrosis (14–17). TGF-β2 modulates the differentiation of various cell types and is considered to increase the production of extracellular matrix, resulting in the formation and contraction of proliferative membranes (18,19). Thus, it is possible that the combination of hyalocytes and TGF-β2 may contribute to the pathogenesis of PVDs.

Statins, inhibitors of the 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase, are widely used to reduce endogenous cholesterol synthesis and improve hypercholesterolemia (20). HMG-CoA reductase is an upstream enzyme in the mevalonate biosynthetic pathway that catalyzes the conversion of HMG-CoA into mevalonate and then, in a number of steps, into farnesylpyrophosphate (FPP), a precursor of cholesterol (21). By inhibiting HMG-CoA reductase, statins block the mevalonate pathway, resulting...
in reduced synthesis of FFP and cholesterol. Statins are divided into three categories: the natural (i.e., lovastatin and pravastatin), the semisynthetic (i.e., simvastatin), and the synthetic (i.e., atorvastatin, fluvastatin, and cerivastatin). Statins decrease the risk for cardiovascular events even among high-risk individuals with coronary disease and diabetes (22). Moreover, statins may be useful in the treatment of other conditions, such as osteoporosis (23) and cancer growth and metastasis (24,25).

Another product of the mevalonate pathway is geranylgeranylporphosphate (GGPP), which is synthesized from FPP. Both FPP and GGPP are important isoprenoid intermediates and serve as lipid attachments for a variety of intracellular proteins to the plasma membrane, including the γ-subunit of heterotrimeric G-proteins and the small GTP-binding proteins, such as Ras and Rho, resulting in their activation (26). Rho translocation from the cytoplasm to the plasma membrane is dependent on geranylgeranylation (GGPP attachment), whereas Ras translocation is dependent on farnesylation (FPP attachment) (27). Rho in the plasma membrane is implicated in the cytoskeletal responses to extracellular signals and is converted to an active GDP-bound state (28). Rho-kinase, one of the effector molecules of Rho, is involved in a variety of cellular events related to cell morphology, adhesion, and motility (28–30), especially through phosphorylation of the myosin light chain (MLC). MLC phosphorylation induces actin-myosin interaction and, consequently, smooth muscle contraction and stress fiber formation in nonmuscle cells (31,32). Activation of the Rho/Rho-kinase pathway is therefore indispensable for smooth muscle contraction. GGPP is one of the downstream components of the mevalonate pathway and plays an important part in the Rho/Rho-kinase pathway activation. Thus, statins, which regulate the mevalonate pathway, also regulate the Rho/Rho-kinase pathway and, consequently, MLC phosphorylation.

Previously, we reported that the Rho-kinase pathway is involved in TGF-β2–induced MLC phosphorylation and contraction of hyalocyte-containing collagen gels and that hydroxyfasudil, a potent Rho-kinase inhibitor, significantly diminishes these TGF-β2–induced effects (18). In the present study, we investigate the regulatory effects of statins on TGF-β2– and vitreous-dependent MLC phosphorylation and contraction of hyalocyte-containing collagen gels and their therapeutic potential for prevention of PVDs in vivo.

**RESEARCH DESIGN AND METHODS**

**Reagents.** Simvastatin, fluvastatin, pravastatin, and cerivastatin were purchased from Calbiochem (La Jolla, CA). Lovastatin was purchased from Funakoshi (Tokyo). Simvastatin was used as an active form after treatment with NaOH.

**Vitreous samples and enzyme-linked immunosorbent assay.** This study was carried out with approval from the Institutional Review Board and performed in accordance with the ethical standards of the 1989 Declaration of Helsinki. We obtained written informed consent from the patients. Vitreous samples were collected from patients who underwent pars plana vitrectomy because of non-PVD (macular hole) or PVD (PDR and PVR). Concentrations of TGF-β2 were measured by a human TGF-β2 immunoassay kit (R&D Systems, Minneapolis, MN).

**Cell culture.** Bovine hyalocytes were isolated as we previously reported (33). Cultured hyalocytes obtained between passages 5 and 7 were used in experiments.

**Collagen gel contraction assay.** The contraction assay was performed as we previously described (33). Type I collagen (Koken, Tokyo), a reconstitution buffer, hyalocytes suspension, and distilled water were mixed and added to a 24-multiwell plate (Nune, Roskilde, Denmark). After 1-h pretreatment of vitreous samples with 1 μg/ml anti-TGF-β2 antibody (R&D Systems) or 1 μg/ml mouse IgG (Sigma-Aldrich) that was added for confirming the absence of nonspecific suppression of the gel contraction by anti-TGF-β2 antibody, the gels were treated with the vitreous samples (400 μl). The diameter of the collagen gel was measured at 5 days after the treatment. For quantitative purposes, contraction data are presented as the reduction in diameter of the collagen gels.

In the same way, collagen gels containing hyalocytes were starved, pretreated with statins for 24 h, and then treated with 3 ng/ml TGF-β2 (Sigma-Aldrich) or vitreous samples. Western blot analysis. Total cell lysates were subjected to 15% SDS-PAGE, and the blots were incubated with an antibody against phosphorylated-MLC (p-MLC; 1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA). Visualization was performed with an enhanced chemiluminescence (ECL; Amersham, Arlington

**FIG. 1.** TGF-β2 expression in the vitreous. A: Vitreous samples were collected from patients with non-PVD (macular hole) and PVD (PDR and PVR). Concentrations of TGF-β2 in the vitreous were measured by enzyme-linked immunosorbent assay (macular hole, n = 27; PDR, n = 53; PVR, n = 22). **p < 0.01 compared with macular hole. B: Hyalocytes were embedded in type I collagen gels (n = 4). After starvation and pretreatment with 1 μg/ml anti-TGF-β2 antibody or 1 μg/ml IgG for 1 h, the collagen gels were treated with vitreous samples from patients with PVD. Five days after the treatment, the gels were photographed. C: The diameter of the collagen gels was measured and expressed as percentage of the average diameter of the control group. *p < 0.05.
Electroretinogram was performed on day 28 as previously described (36). Nine eyes from 10 Dutch rabbits weighing 2–2.5 kg were assigned into three groups. Eyes in the first group (three eyes) were administered an intravitreal injection of 0.1 ml vehicle containing simvastatin (15 μM) and subsequently treated with 3 ng/ml TGF-β2 for 24 h. Total cell lysates were subjected to Western blot analysis with an antibody against p-MLC. Lane loading differences were normalized by reblotting the membranes with an antibody against MLC. C: Hyalocytes were pretreated with or without 5 μM simvastatin for the indicated time (1, 4, 10, and 24 h) and subsequently treated with 3 ng/ml TGF-β2 for 24 h. p-MLC and MLC were also examined in the same way as in Fig. 1A. B and D: Signal intensity ratios (p-MLC to MLC) were expressed as percentage of control intensity ratio. *P < 0.05 compared with TGF-β2 alone.

RESULTS

TGF-β2 in the vitreous and its impact on membrane contraction. The median TGF-β2 protein concentrations, 2.35 ng/ml (range 0.72–5.26) in PDR (n = 27), 4.74 ng/ml (1.60–13.0) in PDR (n = 53), and 4.48 ng/ml (2.52–21.6) in PVR (n = 22) patients, were significantly higher in PDR or PVR patients than in patients with macular hole (P < 0.01) (Fig. 1A). The median TGF-β2 protein concentra-
Bfgels were photographed. Indicated concentrations of simvastatin for 24 h, the collagen gels were control group. *

Measured and expressed as a percentage of the average diameter of contraction was virtually suppressed by specific anti–

Hyalocytes were embedded in type containing nonspecific IgG induced significant contraction

DIABETES, VOL. 57, OCTOBER 2008 2787

Contractions (up to 10 mol/l simvastatin) compared with SS alone, and treatment with 5 μmol/l simvastatin for 24 h significantly suppressed the MLC phosphorylation below that of untreated control (Fig. 2C and D).

TGF-β2–dependent collagen gel contraction and its inhibition by simvastatin. The control gels showed no apparent contraction up to 5 days, whereas TGF-β2 caused substantial collagen gel contraction in a time-dependent manner in the first 5 days (57.6% vs. control). TGF-β2–dependent collagen gel contraction was significantly reduced by simvastatin starting at a concentration of 1 μmol/l, and the reduction was greater at 3 and 10 μmol/l (92 and 100% vs. control, respectively) (Fig. 3).

TGF-β2–dependent Rho translocation to the plasma membrane and its inhibition by simvastatin. TGF-β2 significantly enhanced the Rho translocation to the plasma membrane (P < 0.05), whereas simvastatin suppressed the translocation (Fig. 4A and B). However, the effect of simvastatin was reversed in the presence of 400 μmol/l mevalonate, a component of the mevalonate pathway. These findings suggest that simvastatin inhibits Rho/Rho kinase pathway by preventing Rho from translocating to the plasma membrane via inhibition of the mevalonate pathway. Compare the inhibitory effects of various statins on TGF-β2–dependent MLC phosphorylation and collagen gel contraction. Simvastatin and fluvastatin significantly suppressed TGF-β2–dependent MLC phosphorylation by hyalocytes, whereas pravastatin did not show an effect (Fig. 5A and B). In addition, simvastatin significantly suppressed MLC phosphorylation compared with fluvastatin (P < 0.05). Next, we compared the inhibitory effects of statins on the contraction of hyalocyte-containing collagen gels. Simvastatin and fluvastatin significantly suppressed TGF-β2–dependent contraction of collagen gel, whereas

Comparison of the effects of various statins on TGF-β2–dependent MLC phosphorylation and collagen gel contraction. Simvastatin and fluvastatin significantly suppressed TGF-β2–dependent MLC phosphorylation by hyalocytes, whereas pravastatin did not show an effect (Fig. 5A and B). In addition, simvastatin significantly suppressed MLC phosphorylation compared with fluvastatin (P < 0.05). Next, we compared the inhibitory effects of statins on the contraction of hyalocyte-containing collagen gels. Simvastatin and fluvastatin significantly suppressed TGF-β2–dependent contraction of collagen gel, whereas

Contractions in the vitreous samples from patients with PDR or PVR showed no significant difference (P = 0.6). Vitreous samples from patients with PVD and those containing nonspecific IgG induced significant contraction of hyalocyte-containing collagen gels (63 and 67% vs. control, respectively). In comparison, the vitreous-induced contraction was virtually suppressed by specific anti–TGF-β2 antibody (P < 0.05) (97% vs. control) (Fig. 1B and C), suggesting a key role for TGF-β2 in the vitreous-induced collagen gel contraction.

Role of simvastatin in TGF-β2–dependent MLC phosphorylation. TGF-β2 enhanced MLC phosphorylation to about two times that seen with control (Fig. 2A and B). TGF-β2–dependent MLC phosphorylation showed a significant reduction at 0.3 μmol/l simvastatin or higher concentrations (up to 10 μmol/l simvastatin) compared with TGF-β2 alone (P < 0.05). The level of MLC phosphorylation at 10 μmol/l simvastatin concentration was lower than in untreated control, suggesting that simvastatin at higher concentrations may block the constitutive level of MLC phosphorylation. Because 3 μmol/l simvastatin was sufficient to reverse the effect of TGF-β2 on MLC phosphorylation, we chose the slightly higher concentration of 5 μmol/l to study the time-dependent effect of simvastatin on TGF-β2–dependent MLC phosphorylation. Treatment of the hyalocytes with 5 μmol/l simvastatin for 1 h or longer (up to 24 h) significantly suppressed the MLC phosphorylation compared with TGF-β2 alone, and treatment with 5 μmol/l simvastatin for 24 h sufficiently suppressed the MLC phosphorylation compared with fluvastatin and its inhibition by simvastatin. The control gels showed no apparent contraction up to 5 days, whereas TGF-β2 caused substantial collagen gel contraction in a time-dependent manner in the first 5 days (57.6% vs. control). TGF-β2–dependent collagen gel contraction was significantly reduced by simvastatin starting at a concentration of 1 μmol/l, and the reduction was greater at 3 and 10 μmol/l (92 and 100% vs. control, respectively) (Fig. 3).
pravastatin did not show an effect (Fig. 5C and D). In addition, the inhibitory effect of simvastatin (100% vs. control) was significantly higher than that by fluvastatin (94% vs. control) (P < 0.05). To test whether cytokine and/or statin treatment affected the growth and/or viability of the cells in our experiments, we treated the collagen gels with collagenase and counted the number of viable cells. Both TGF-β2 and statins showed no significant effects on cell number in the three-dimensional collagen gels (Fig. 5E).

Impact of simvastatin on MLC phosphorylation and collagen gel contraction induced by vitreous samples from patients with PVD. Vitreous samples from patients with PVD caused a significantly larger enhancement of MLC phosphorylation than those from patients with non-PVD (Fig. 6A and B). Simvastatin (5 μmol/l) strongly attenuated the vitreous-induced MLC phosphorylation. Expression of GAPDH did not change after the treatment with simvastatin or stimulation with vitreous samples. However, total MLC increased in cells stimulated with the vitreous samples, and the increase was larger in cells stimulated with vitreous samples from patients with PVD than those from patients without PVD. These increases in an amount of total MLC were suppressed by 5 μmol/l simvastatin.

The contraction of hyalocyte-containing collagen gels stimulated with the vitreous samples from patients with PVD was significantly larger compared with the contrac-
tion of the gels stimulated with vitreous samples from patients without PVD (Fig. 6C and D). We further examined the inhibitory effect of simvastatin on vitreous-dependent contraction of collagen gels and found that 5 μmol/l simvastatin suppressed the collagen gel contraction induced by vitreous samples even from patients with PVD.

**Simvastatin inhibition of PVR development in vivo.** The control eyes of rabbits injected with vehicle developed PVR and were accompanied by proliferative membrane formation and cicatricial contraction, resulting in tractional retinal detachment (Fig. 7A). In comparison, 5 and 15 μmol/l simvastatin (final intravitreal concentrations) significantly prevented PVR development (Fig. 7C). Simvastatin inhibited the contraction of the proliferative membrane, and the membranes in eyes treated with simvastatin were much thinner than those in vehicle-treated eyes (Fig. 7B). After simvastatin injections were stopped at day 7, the eyes treated with 5 μmol/l simvastatin developed a mild but significant PVR, whereas no significant PVR development was observed in the eyes treated with 15 μmol/l simvastatin.

**Absence of apparent adverse effects of simvastatin in the retina.** To evaluate the retinal function after intravitreal application of simvastatin, we performed electroretinography. The mean amplitude and latency of the 2Hz b wave in the eyes treated with 5 or 15 μmol/l simvastatin were 203.4 ± 19.3 V and 28.1 ± 1.4 ms and 201.7 ± 13.2 V and 28.4 ± 2.6 ms, respectively, and were not significantly different from those without any treatment or those of the vehicle-treated eyes (204.8 ± 17.6 V and 28.1 ± 1.4 ms), suggesting that at these concentrations, simvastatin may not impede retinal function (Fig. 8A).

The histological structure of the retina in the eyes injected with simvastatin appeared normal when observed on day 28 (Fig. 8B, C). In the retina of an experimental PVR used as a positive-control, apoptotic cells, which present TUNEL-positive staining (green), were detected in the inner nuclear layer and the outer nuclear layer (Fig. 8D). The eyes injected with simvastatin had no apparent TUNEL-positive staining in the retina when observed on day 28 (Fig. 8E). The eyes injected with simvastatin had no apparent ultrastructural changes in internal limiting membrane,
nerve fiber layer, and ganglion cell layer (Fig. 8G) compared with the untreated control eyes (Fig. 8F). In other parts of the retina, such as inner and outer nuclear layers, photoreceptors, and retinal pigment epitheliums, there were also no apparent changes.

**DISCUSSION**

Blindness is a devastating consequence of PVDs such as PDR and PVR. Currently, the progression of these diseases cannot be effectively prevented, and the treatment options are limited to vitreoretinal surgery. An effective pharmacological treatment is thus urgently needed to complement or potentially replace the surgical intervention. In the current study, we show statins’ novel function in inhibiting the Rho/Rho-kinase pathway, the contraction of collagen gel, and the progression of experimental PVR, suggesting the therapeutic potential of these compounds for the treatment of PVDs.

Various cytokines, such as TGF-β, connective tissue growth factor, interleukin-6, and platelet-derived growth factor (PDGF), are overexpressed in the vitreous and membranes associated with PDR and PVR, and they contribute to the pathogenesis of these diseases (15,37–40). Among these cytokines, TGF-β2 induces the transformation of retinal pigment epithelial cells or hyalocytes to myofibroblastic cells (18,41) and plays a key role in the formation and contraction of proliferative membranes. In this study, we confirmed the overexpression of TGF-β2 in the vitreous from patients with PVD (PDR and PVR) and showed that TGF-β2 inhibition strongly suppressed the vitreous-induced contraction of the collagen gels. This indicates the possibility that TGF-β2 is the dominant contributor to the contraction of proliferative membrane in the vitreous cavity. Thus, we focused on the role of TGF-β2 to investigate the mechanisms of membrane contraction. TGF-β2 enhanced MLC phosphorylation and collagen gel contraction in a dose-dependent fashion by inhibiting GGPP-mediated translocation of Rho to the plasma membrane, whereas no signs of cytotoxicity were apparent.

Differences in the structural characteristics of statin cause different levels of lipophilicity and possibly of efficacies and also cytotoxicity. Pravastatin is strongly hydrophilic, and simvastatin is much more lipophilic than pravastatin (42). Fluvastatin is also more lipophilic than pravastatin; however, it is less lipophilic than simvastatin (43). Although our comparison of the inhibitory effects of various statins, simvastatin, fluvastatin, and pravastatin, revealed that simvastatin was more effective in reducing MLC phosphorylation than the other statins under the chosen experimental conditions, the results might vary at other time points or concentrations. Further examination is necessary to determine the order. Additionally, because cerivastatin is more lipophilic than simvastatin (44), we studied the effects of cerivastatin and simvastatin. Many hyalocytes treated with 5 μmol/l cerivastatin for 24 h shrank and detached from the culture plates, whereas the cells treated with 5 μmol/l simvastatin remained morphologically unchanged. However, at higher concentrations (>20 μmol/l), some hyalocyte shrinkage was observed even with simvastatin (data not shown). Cerivastatin is known to be cytotoxic and induce apoptosis (45). The morphological changes we observed in cerivastatin-treated hyalocytes in our study suggest that this drug may also be toxic to hyalocytes and promote their apoptosis. Because the lipophilicity of lovastatin is similar to that of simvastatin (42), we compared their effect and found the inhibitory effect of simvastatin on MLC phosphorylation and collagen gel contraction to be greater than that of 5 μmol/l lovastatin for 24 h (data not shown).

Vitreous samples from patients with PDR and PVR induced MLC phosphorylation and contraction of hyalocyte-containing collagen gels, which were effectively inhibited by simvastatin. It may appear surprising that not only vitreous samples from patients with PVD but also those from non-PVD patients induced MLC phosphorylation and collagen gel contraction. However, this might be explained by the fact that TGF-β2 is expressed in vitreous samples of patients with macular hole at high enough concentrations to induce the observed phenomena. The concentrations of TGF-β2 in vitreous samples from patients with PVD (PDR and PVR) were higher than in those from macular hole patients. Therefore, in a concentration-dependent manner, the inductions might be greater in the vitreous samples.
from patients with PVD than in those from patients without PVD. The concentrations of TGF-β2 in some vitreous samples from patients with macular hole were higher than those with PDR and PVR. However, the pathology of macular hole does not generally involve proliferative membrane formation and tractional retinal detachment. Occasionally, epiretinal membranes and retinal folds accompany macular hole. Retinal folds are considered to be caused by the contraction of the epiretinal membranes. TGF-β2 concentrations in vitreous samples from patients with macular hole may be high enough to induce contraction of proliferative membranes, however, because the epiretinal membrane in these patients does not extend into the vitreous and is very thin; the expression of TGF-β2 remains inconsequential.

MLC phosphorylation depends on the concentration of TGF-β2 (18); thus, the eyes with PVR having lower TGF-β2 concentrations might represent a less severe pathology, or remission, compared with those with higher TGF-β2 concentrations. The occurrence of tractional retinal detachment might depend on the presence or absence of proliferative membranes and the concentration of TGF-β2.

Although TGF-β2–stimulated hyalocytes showed no significant change in MLC expression, those stimulated with vitreous samples showed elevated MLC expression that was inhibited by simvastatin treatment. The vitreous in-

**FIG. 8.** Histological and physiological examinations of eyes injected with simvastatin. Rabbits received intravitreal injections of 0.1 ml vehicle or vehicle with simvastatin (final concentration of 5 or 15 μmol/l simvastatin) on days 0, 1, 3, 5, and 7. A: Electretinograms on day 28. A flash stimulus of intensity 1.30 log cd.s/m² was superimposed on a background luminance of 1.15 log cd/m². Light microscopy of the rabbit eye without any treatment (B) and that of the eye injected with 15 μmol/l simvastatin (C). Scale bar = 100 μm. Apoptotic and potentially necrotic cell death detected by TUNEL in the section from positive control (rabbit PVR model on day 7 after its onset) (D) and in the section from the 15 μmol/l simvastatin-treated eye (E). Scale bar = 50 μm. Transmission electron microscopy of the rabbit eye without treatment (F) and that of the eye injected with 15 μmol/l simvastatin (G). Scale bar = 10 μm. (Please see http://dx.doi.org/10.2337/db08-0302 for a high-quality digital representation of this image.)
cludes various cytokines, released from retinal pigment epithelial cells, glial cells, macrophages, and other intravitreal cells (46). Thus, some cytokines other than TGF-β2 might elevate the expression of MLC. Among the cytokines found in the vitreous, insulin-like growth factor-1 (IGF-I), PDGF, and members of the endothelin family have been shown to stimulate extracellular matrix contraction (18,47,48). This study reveals a key role for TGF-β2 in the pathology of PVDs; however, it is possible that other cytokines found in the vitreous might also be involved in MLC phosphorylation and contraction of hyalocyte-containing collagen gels. Because simvastatin almost completely inhibited the phenomena induced by vitreous samples, it might also inhibit the effect of the other cytokines, such as IGF-I, PDGF, and members of the endothelin family and unknowns, which might be exerted through the Rho/Rho-kinase pathway.

Simvastatin also prevented the development of PVR in vivo. Proliferative membranes in simvastatin-injected eyes, even if present, were very thin, whereas the membranes in vehicle injected eyes with PVR in stage 4 or 5 were thick. Thus, simvastatin might have also an inhibitory effect on the formation and growth of proliferative membranes in addition to the cicatrificial contraction of proliferative membranes. However, at the end of the simvastatin injections, even in the groups treated with higher concentration of simvastatin (15 μmol/l) the development of PVR was not completely inhibited. This may be due to a short biological half-life time of the compound in the vitreous cavity. Therefore, to sustain a constant level of intravitreal simvastatin concentration, frequent injections or a slow release drug delivery system might be necessary.

Recent findings suggest that statins might have a number of beneficial effects in the eye. Although the applicability of statins on age-related macular degeneration is still under investigation (49), statins are shown to have protective effects on primary open-angle glaucoma, a major cause of blindness (50). The regulation of the intraocular pressure (IOP) within a physiological range is of great clinical importance. Statins are reported to downregulate the IOP by increasing aqueous humor outflow via the inhibition of Rho/Rho-kinase pathway in the trabecular meshwork and the ciliary body (50).

In conclusion, simvastatin potently inhibits the Rho/Rho-kinase pathway and thus might have therapeutic potential in the prevention of cicatricial contraction of proliferative membranes in vivo. This is the first report demonstrating the beneficial effects of simvastatin in inhibiting the development of PVR. Statins might provide a new strategy for the treatment and prevention of the development of PVDs in humans.

ACKNOWLEDGMENTS

S.N. has received a Research Fellowship Award from Bausch & Lomb and a Fellowship Award from the Japan Eye Bank Association. A.H.-M. has received National Institutes of Health Grants AI050775 and HL086933. This study has received Grants-in-Aid for Scientific Research 19592026, 18791283, and 18591925 from the Ministry of Education, Science, Sports and Culture, Japan; National Eye Institute Core Grant EY14104; and support from the Massachusetts Lions Eye Research Fund, the Marion W. and Edward F. Knight Age-Related and Macular Degeneration Fund, and Research to Prevent Blindness.

We acknowledge David Goodman (Pharmascience), Waichiro Katsuda, Tomoko Saeki, and Noriyuki Yoshida (Agumen Biopharmaceuticals) for their excellent help.

REFERENCES

1. Pastor JC, de la Rua ER, Martin F: Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 21:127–144, 2002
2. Pastor JC: Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 43:3–18, 1998
3. Frielander M: Fibrosis and diseases of the eye. J Clin Invest 117:576–586, 2001
4. Campochiaro PA: Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol 115:237–241, 1997
5. Jordan JA, Pepose JS, Michels RG, Hayashi H, de Bustros S, Sebag M, Glaser BM: Proliferative vitreoretinopathy membranes: an immunohistochemical study. Ophthalmology 96:801–810, 1989
6. Vincera SA, Campochiaro PA, Conway BP: Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci 31:11–28, 1990
7. Machemer R, Lagua H: Pignent epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol 80:1–23, 1975
8. Lazarus HS, Hageman GS: In situ characterization of the human hyalocyte. Arch Ophthalmol 112:1356–1362, 1994
9. Grabner G, Boltz G, Forster O: Macroglage-like properties of human hyaloctyes. Invest Ophthalmol Vis Sci 19:333–340, 1980
10. Mitchell CA, Risau W, Drexler HC: Regression of vessels in the tunica vasculosa lentis is initiated by coordinated endothelial apoptosis: a role for vascular endothelial growth factor as a survival factor for endothelium. Dev Dyn 213:322–333, 1998
11. Kamilik A, Kenyon KR, Michels RG, Green WR, de la Cruz ZC: Epiretinal and vitreous membranes: comparative study of 56 cases. Arch Ophthalmol 99:1445–1451, 1981
12. Faulborn J, Dunker S, Bawold S: Diabetic vitreopathy: findings using the cellodin embedding technique. Ophthalmologica 212:369–376, 1998
13. Pfeffer BA, Flanders KC, Guerin CJ, Danielpour D, Anderson DI: Transforming growth factor beta-2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the monkey eye. Exp Eye Res 59:523–533, 1994
14. Connor TB Jr, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H, Lansing M: Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 83:1601–1606, 1989
15. Kita T, Hata Y, Kano K, Miura M, Nakao S, Noda Y, Shimokawa H, Ishibashi T: Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyaloctyes and therapeutic potential of Rho kinase inhibitor. Diabetes 56:231–238, 2007
16. Ando A, Ueda M, Uyama M, Masu Y, Ito S: Enhancement of dedifferentiation and myoid differentiation of retinal pigment epithelial cells by platelet derived growth factor. Br J Ophthalmol 84:1306–1311, 2000
17. Vincera SA, Henderer JD, Mahlow J, Chiu C, Derveyjanik NL, Larochelle W, Csakly C, Campochiaro PA: Isomorphism of platelet-derived growth factor and its receptors in epiretinal membranes: immunolocalization to retinal pigmented epithelial cells. Exp Eye Res 60:607–619, 1995
18. Hirayama K, Hata Y, Noda M, Tsutsumi K, Shimokawa H, Ishibashi T: The involvement of the rho-kinase pathway and its regulation in cytokine-induced collagen gel contraction by hyaloctyes. Invest Ophthalmol Vis Sci 45:899–900, 2004
19. Jester JV, Ho-Chang J: Modulation of cultured corneal keratocyte phenotype by growth factors/cytokines control in vitro contractility and extracellular matrix contraction. Exp Eye Res 77:581–592, 2003
20. Molgaard J, von Schenck H, Olsson AG: Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia. Eur Heart J 9:541–551, 1988
21. Graef MB, Briel C, van Noorden CJ, Guchelaar HJ: Effects of statins and cancer. Curr Opin Oncol 20,536:7–22, 2002
22. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin and other while LDL cholesterol, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia. Eur Heart J 9:541–551, 1988
23. Graef MB, Briel C, van Noorden CJ, Guchelaar HJ: Effects of statins and cancer. Curr Opin Oncol 20,536:7–22, 2002
24. Coons JC: Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann Pharmacother 36:326–330, 2002
25. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC: Breast cancer growth prevention by statins. Cancer Res 66:8707–8714, 2006
25. Matar P, Rozados VR, Binda MM, Roggero EA, Bonfill RD, Scharovsky OG: Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. *Clin Exp Metastasis* 17:19–25, 1990

26. Van Aelst L, D’Souza-Schorey C: Rho GTPases and signaling networks. *Genes Dev* 11:2295–2322, 1997

27. Laufs U, Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. *J Biol Chem* 273:24266–24271, 1998

28. Hall A: Rho GTPases and the actin cytoskeleton. *Science* 279:509–514, 1998

29. Paterson HF, Self AJ, Garrett MD, Just I, Aktories K, Hall A: Microinjection of recombinant p21rho induces rapid changes in cell morphology. *J Cell Biol* 111:1001–1007, 1990

30. Takaishi K, Sasaki T, Kato M, Yamochi W, Kuroda S, Nakamura T, Takeichi M, Takai Y: Involvement of Rho p21 small GTP-binding protein and its regulator in the HGF-induced cell motility. *Oncogene* 9:273–279, 1994

31. Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, Kaibuchi K, Ito M: Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. *J Biol Chem* 272:12257–12260, 1997

32. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K: Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. *Science* 275:1308–1311, 1997

33. Noda Y, Hata Y, Hisatomi T, Nakamura Y, Hirayama K, Miura M, Nakao S, Dong X, Chen N, Xie L, Wang S: Prevention of experimental proliferative vitreoretinopathy by a biodegradable intravitreal drug delivery system of all-trans retinoic acid. *Invest Ophthalmol Vis Sci* 35:3649–3663, 1994

34. Fastenberg DM, Diddie KR, Dorey K, Ryan SJ: The role of cellular receptors immunolocalized in proliferative retinal diseases. *Exp Eye Res* 76:333–340, 2003

35. Hamelin BA, Turgeon J: Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. *Trends Pharmacol Sci* 19:26–37, 1998

36. Robins SG, Mixon RN, Wilson DJ, Hart CE, Weitz S, Usinger W, LaBree L, Oliver N, Lim JI: Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. *Br J Ophthalmol* 85:461–470, 2001

37. Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I, Planck SR, Rosenbaum JT: Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. *Invest Ophthalmol Vis Sci* 35:3649–3663, 1994

38. Hinton DR, Spee C, He S, Weitz S, Usinger W, LaBree L, Oliver N, Lim JJ: Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. *Diabetes Care* 27:758–764, 2004

39. Hinton DR, He S, Jin ML, Barron E, Ryan SJ: Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. *Eye* 16:422–428, 2002

40. Serajuddin AT, Ranadive SA, Mahoney EM: Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. *J Pharm Sci* 80:830–834, 1991

41. Gamaleus MA, Chen Y, He S, Spee C, Jin M, Ryan SJ, Hinton DR: Transforming growth factor beta2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor. *Exp Eye Res* 83:212–222, 2006

42. Serajuddin AT, Ranadive SA, Mahoney EM: Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. *J Pharm Sci* 80:830–834, 1991

43. Hamelin BA, Turgeon J: Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. *Trends Pharmacol Sci* 19:26–37, 1998

44. Chauhan NB, Siegel GJ, Feinstein DL: Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. *Neurochem Res* 29:1897–1911, 2004

45. Kobayashi M, Kaido F, Kagawa T, Itagaki S, Hirano T, Iseki K: Preventive effects of bicarbonate on cerivastatin-induced apoptosis. *Int J Pharm* 341:181–188, 2007

46. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe P: Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. *Br J Ophthalmol* 85:461–470, 2001

47. Guidry C, Hook M: Endothelins produced by endothelial cells promote collagen gel contraction by fibroblasts. *J Cell Biol* 115:873–880, 1996

48. Guidry C: Tractional force generation by porcine Muller cells: development and differential stimulation by growth factors. *Invest Ophthalmol Vis Sci* 38:456–468, 1997

49. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL: Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. *Am J Ophthalmol* 137:615–624, 2004

50. Song J, Deng PF, Stinnett SS, Epstein DL, Rao PV: Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. *Invest Ophthalmol Vis Sci* 46:2424–2432, 2005